To hear about similar clinical trials, please enter your email below
Trial Title:
Musculoskeletal Health in Adult Haematological Cancer Survivors
NCT ID:
NCT05865678
Condition:
Lymphoma
Leukemia
Cancer Survivors
Musculoskeletal Complication
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Other
Intervention name:
Not an intervention study
Description:
This is a study administering questionnaire and interviews using mixed quantitative and
qualitative methodology with the aim to describe and evaluate musculoskeletal health of
adult haematological cancer survivors and its impact to survivors.
Arm group label:
11-20 years post cancer treatment; female; age at diagnosis 18-30
Arm group label:
11-20 years post cancer treatment; female; age at diagnosis 31-50
Arm group label:
11-20 years post cancer treatment; female; age at diagnosis 51-70
Arm group label:
11-20 years post cancer treatment; female; age at diagnosis 70+
Arm group label:
11-20 years post cancer treatment; male; age at diagnosis 18-30
Arm group label:
11-20 years post cancer treatment; male; age at diagnosis 31-50
Arm group label:
11-20 years post cancer treatment; male; age at diagnosis 51-70
Arm group label:
11-20 years post cancer treatment; male; age at diagnosis 70+
Arm group label:
21-30 years post cancer treatment; female; age at diagnosis 18-30
Arm group label:
21-30 years post cancer treatment; female; age at diagnosis 31-50
Arm group label:
21-30 years post cancer treatment; female; age at diagnosis 51-70
Arm group label:
21-30 years post cancer treatment; female; age at diagnosis 70+
Arm group label:
21-30 years post cancer treatment; male; age at diagnosis 18-30
Arm group label:
21-30 years post cancer treatment; male; age at diagnosis 31-50
Arm group label:
21-30 years post cancer treatment; male; age at diagnosis 51-70
Arm group label:
21-30 years post cancer treatment; male; age at diagnosis 70+
Arm group label:
30 years + post cancer treatment; female; age at diagnosis 18-30
Arm group label:
30 years + post cancer treatment; female; age at diagnosis 31-50
Arm group label:
30 years + post cancer treatment; female; age at diagnosis 51-70
Arm group label:
30 years + post cancer treatment; female; age at diagnosis 70+
Arm group label:
30 years + post cancer treatment; male; age at diagnosis 18-30
Arm group label:
30 years + post cancer treatment; male; age at diagnosis 31-50
Arm group label:
30 years + post cancer treatment; male; age at diagnosis 51-70
Arm group label:
30 years + post cancer treatment; male; age at diagnosis 70+
Arm group label:
5-10 years post cancer treatment; female; age at diagnosis 18-30
Arm group label:
5-10 years post cancer treatment; female; age at diagnosis 31-50
Arm group label:
5-10 years post cancer treatment; female; age at diagnosis 51-70
Arm group label:
5-10 years post cancer treatment; female; age at diagnosis 70+
Arm group label:
5-10 years post cancer treatment; male; age at diagnosis 18-30
Arm group label:
5-10 years post cancer treatment; male; age at diagnosis 31-50
Arm group label:
5-10 years post cancer treatment; male; age at diagnosis 51-70
Arm group label:
5-10 years post cancer treatment; male; age at diagnosis 70+
Summary:
Haematological cancer treatment often includes use of high dose glucocorticoids
(steroids), chemotherapy and radiotherapy and current evidence suggests that these
patients may have lower bone mineral density after treatment when compared to the general
population which can predispose them to increased risk of fragility fractures. Evidence
of the impact of these musculoskeletal burden to patients (e.g. quality of life) are not
available.
This study aims to describe musculoskeletal complications experienced by long-term
haematological cancer survivors and examine the impact of the burden from the patient
perspective. The study will be conducted in 2 parts; a questionnaire study and an
interview study to help understand the extent of musculoskeletal problems experienced by
this group of patients and the impact of this on quality of life.
Criteria for eligibility:
Study pop:
Participants will be identified from The Christie NHS Foundation Trust local haematology
and lymphoma survivors' clinical patient databases. The haematology database used is the
HSCT database that records all haematology patients that have undergo haematopoietic stem
cell transplant. For lymphoma patients, the ADAPT (Managed Local Follow up of Long-Term
Lymphoma Survivors) database will be used which records lymphoma patients that are cured
and had 5 years regular hospital follow up post treatment.
Sampling method:
Probability Sample
Criteria:
Questionnaire study
Inclusion Criteria:
1. Age 18 or above at diagnosis of haematological cancer
2. Diagnosis of haematological cancers: lymphoma or leukaemia
3. Cancer survivors as recorded in the local database of lymphoma and haematopoietic
stem cell transplant database
4. Able to give written informed consent
5. Able to read and understand English
Exclusion Criteria:
1.Currently receiving any active cancer treatment
Interview study
Inclusion Criteria:
1. Age 18 or above at diagnosis of haematological cancer
2. Diagnosis of haematological cancers: lymphoma or leukaemia
3. Cancer survivors as recorded in the local database of lymphoma and haematopoietic
stem cell transplant database
4. Able to give written or verbal informed consent
5. Able to read and understand English
Exclusion Criteria:
1 .Currently receiving any active cancer treatment
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
The Christie NHS Foundation Trust
Address:
City:
Manchester
Zip:
M20 4BX
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Salina Tsui
Phone:
07726781196
Email:
salina.tsui@nhs.net
Start date:
May 2, 2023
Completion date:
May 2024
Lead sponsor:
Agency:
The Christie NHS Foundation Trust
Agency class:
Other
Collaborator:
Agency:
National Institute for Health Research, United Kingdom
Agency class:
Other
Source:
The Christie NHS Foundation Trust
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05865678
